二价AS04佐剂HPV疫苗接种后由非疫苗可预防HPV型别引起的癌前宫颈病变:随机哥斯达黎加HPV疫苗试验长期随访研究分析
该研究为哥斯达黎加HPV疫苗试验(CVT)长期随访阶段分析,评估二价AS04佐剂HPV疫苗对非疫苗可预防HPV型别所致CIN2+和CIN3+的疫苗效力。第7-11年观察到临床揭盲现象:疫苗组非可预防型别所致CIN2+的疫苗效力为-71.2%(95%CI -164.0至-12.5),CIN3+为-135.0%(95%CI -329.8至-33.5)。作者认为临床揭盲可能削弱疫苗接种对高级别病变的长期下降效果,但疫苗净获益仍相当可观。
要点
- 第7-11年疫苗组非可预防HPV型别所致CIN2+疫苗效力为-71.2%(95%CI -164.0至-12.5),出现临床揭盲。
- 每1000名接种者较未接种者多9.2例(95%CI 2.1至15.6)非可预防型别所致CIN2+事件。
- 11年随访中每1000名接种者任意HPV型别CIN2+事件减少27.0例(95%CI 14.2至39.9)。
核心结论
- 作者认为,疫苗组较未接种组非可预防HPV型别所致CIN2+和CIN3+事件发生率更高,提示临床揭盲可能削弱HPV疫苗接种规划在筛查人群中带来的高级别病变长期下降。
- 作者指出疫苗的净获益仍相当可观,因此HPV疫苗接种仍应作为宫颈癌一级预防的优先事项。
研究设计与样本
- CVT为在哥斯达黎加开展的随机、双盲、社区为基础的试验,纳入18-25岁一般健康状况良好的女性。
- 2004年6月28日至2005年12月21日共入组7466名参与者,HPV疫苗组3727名,甲型肝炎病毒疫苗对照组3739名。
- 2009年3月30日至2012年7月5日新入组2836名未接种对照组成员;疫苗组与未接种对照组随访7年,该阶段治疗分配不设盲。
- 主要分析期为第7-11年,主要分析人群为至少有一次随访且排除既往终点事件者(改良意向治疗队列)。
主要发现
- CIN2+终点评估的主要分析队列包括HPV疫苗组2767名和未接种组2563名;CIN3+终点评估包括疫苗组2826名和未接种对照组2592名。
- 第7-11年CIN2+分析纳入女性的中位随访时间:HPV疫苗组52.8个月(IQR 44.0至60.7),未接种对照组49.8个月(IQR 42.0至56.9)。
- 第7-11年非可预防HPV型别所致CIN2+的疫苗效力为-71.2%(95%CI -164.0至-12.5),每1000名接种者较未接种者多9.2例(95%CI 2.1至15.6)。
- 11年随访中每1000名接种者任意HPV型别CIN2+事件减少27.0例(95%CI 14.2至39.9)。
- 第7-11年非可预防HPV型别所致CIN3+的疫苗效力为-135.0%(95%CI -329.8至-33.5),每1000名接种者较未接种者多8.3例(95%CI 3.0至12.8)。
临床怎么用
- 作者建议HPV疫苗接种仍应作为宫颈癌一级预防的优先事项。
局限性
- 第7-11年非可预防HPV型别所致CIN2+的疫苗效力95%CI为-164.0至-12.5,CIN3+为-329.8至-33.5,置信区间较宽。
- 随机、设盲试验阶段结束后,疫苗组与未接种对照组的随访阶段治疗分配不设盲。
- 非可预防HPV型别所致CIN2+和CIN3+事件的绝对数较少,每1000名接种者分别多9.2例和8.3例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In women vaccinated against human papillomavirus (HPV), reductions in cervical disease and related procedures results in more women having intact transformation zones, potentially increasing the risk of cervical lesions caused by non-vaccine-preventable HPV types, a phenomenon termed clinical unmasking. We aimed to evaluate HPV vaccine efficacy against cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) attributed to non-preventable HPV types in the long-term follow-up phase of the Costa Rica HPV Vaccine Trial (CVT). METHODS: CVT was a randomised, double-blind, community-based trial done in Costa Rica. Eligible participants were women aged 18-25 years who were in general good health. Participants were randomly assigned (1:1) to receive an HPV 16 and 18 AS04-adjuvanted vaccine or control hepatitis A vaccine, using a blocked randomisation method (permuted block sizes of 14, 16, and 18). Vaccines in both groups were administered intramuscularly with 0·5 mL doses at 0, 1, and 6 months. Masking of vaccine allocation was maintained throughout the 4-year randomised trial phase, after which participants in the hepatitis A virus vaccine control group were provided the HPV vaccine and exited the study; a screening-only, unvaccinated control group was enrolled. The unvaccinated control group and HPV vaccine group were followed up for 7 years, during which treatment allocation was not masked. One of the prespecified primary endpoints for the long-term follow-up phase was precancers associated with HPV types not prevented by the vaccine, defined as histologically confirmed incident CIN2+ events or CIN3+ events attributed to any HPV type except HPV 16, 18, 31, 33, and 45. Our primary analytical period was years 7-11. Primary analyses were in all participants with at least one follow-up visit and excluded participants with a previous endpoint (ie, modified intention-to-treat cohort). Safety endpoints have been reported elsewhere. This trial is registered with ClinicalTrials.gov, NCT00128661 and NCT00867464. The randomised, masked trial phase is completed; an unmasked subset of women in the HPV-vaccinated group is under active investigation. FINDINGS: Between June 28, 2004, and Dec 21, 2005, 7466 participants were enrolled (HPV vaccine group n=3727 and hepatitis A virus vaccine control group n=3739). Between March 30, 2009, and July 5, 2012, 2836 women enrolled in the new unvaccinated control group. The primary analytical cohort (years 7 to 11) included 2767 participants in the HPV vaccine group and 2563 in the unvaccinated group for the CIN2+ events endpoint assessment and 2826 participants in the HPV vaccine group and 2592 in the unvaccinated control group for the CIN3+ events endpoint assessment. Median follow-up during years 7 to 11 for women included for the CIN2+ events analysis was 52·8 months (IQR 44·0 to 60·7) for the HPV vaccine group and 49·8 months (42·0 to 56·9) for the unvaccinated control group. During years 7 to 11, clinical unmasking was observed with a negative vaccine efficacy against CIN2+ events attributed to non-preventable HPV types (-71·2% [95% CI -164·0 to -12·5]), with 9·2 (95% CI 2·1 to 15·6) additional CIN2+ events attributed to non-preventable HPV types per 1000 HPV-vaccinated participants versus HPV-unvaccinated participants. 27·0 (95% CI 14·2 to 39·9) fewer CIN2+ events irrespective of HPV type per 1000 vaccinated participants were observed during 11 years of follow-up. Vaccine efficacy against CIN3+ events attributed to non-preventable HPV types during years 7 to 11 was -135·0% (95% CI -329·8 to -33·5), with 8·3 (3·0 to 12·8) additional CIN3+ events attributed to non-preventable HPV types per 1000 vaccinated participants versus unvaccinated participants. INTERPRETATION: Higher rates of CIN2+ events and CIN3+ events due to non-preventable HPV types in vaccinated versus unvaccinated participants suggests clinical unmasking could attenuate long-term reductions in high-grade disease following successful implementation of HPV vaccination programmes in screened populations. Importantly, the net benefit of vaccination remains considerable; therefore, HPV vaccination should still be prioritised as primary prevention for cervical cancer. FUNDING: National Cancer Institute and National Institutes of Health Office of Research on Women's Health. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.
引用
- Shing JZ, Hu S, Herrero R, et al. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022. PMID: 35709811. doi:10.1016/S1470-2045(22)00291-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。